Quanterix Leadership to Present at Key Healthcare Conferences in March
Event summary
- Quanterix executives to participate in TD Cowen and Leerink healthcare conferences in March 2026
- Fireside chats scheduled for March 4 and March 9, with webcasts available
- Company highlights integration of Akoya Biosciences' spatial biology technology
- Quanterix operates 1,396 installed instruments post-acquisition
- Executive leadership team to engage in one-on-one investor meetings
The big picture
Quanterix's participation in these investor conferences comes as the company integrates its 2025 Akoya Biosciences acquisition, creating a unique platform connecting blood and tissue analysis. The presentations will be closely watched as investors assess the company's ability to leverage this integrated technology in the precision medicine market. With approximately 6,000 peer-reviewed publications supporting its technology, Quanterix aims to demonstrate its leadership position in ultra-sensitive biomarker detection.
What we're watching
- Integration Progress
- How Quanterix will demonstrate the strategic value of the Akoya Biosciences acquisition to investors
- Market Positioning
- Whether the combined blood and tissue analysis platform can differentiate Quanterix in the competitive diagnostics space
- Investor Sentiment
- The reception of Quanterix's growth strategy at high-profile healthcare investor conferences
Related topics